Vishal Chakravarty is a contributing author to Yakuji Nippo (薬事日報) — Japan's foremost pharmaceutical daily, founded 1945. Four published articles covering the full spectrum of UK pharmaceutical market access: MHRA post-Brexit pathways, PLPI licensing, parallel import strategy, and NICE Health Technology Assessment. Available in English and Japanese.
Lead Article
An analysis of how pharmaceutical companies can successfully navigate the UK's post-Brexit regulatory environment — covering MHRA marketing authorisation pathways, product registration procedures, and distribution strategies that now diverge from the EMA framework following Brexit. Essential reading for international pharma companies seeking UK market entry.
All Articles
All four articles are published in Yakuji Nippo and available in both English and Japanese — written from direct operational experience building NovaPharm Healthcare under MHRA and EMA oversight.
An analysis of how pharmaceutical companies can successfully navigate the UK's post-Brexit regulatory environment — covering MHRA marketing authorisation pathways, product registration procedures, and distribution strategies that now diverge from the EMA framework following Brexit.
A detailed operational guide for international pharmaceutical companies seeking to obtain MHRA Parallel Import Product Licences (PLPI) in the United Kingdom — covering application requirements, regulatory timelines, compliance obligations, pharmacovigilance reporting, and post-licence maintenance procedures.
A strategic examination of pharmaceutical parallel importation across UK and EU markets — addressing MHRA and EMA licensing obligations, cross-border pricing differentials, product re-labelling and re-packaging requirements, GDP compliance in transit, and risk management frameworks for parallel import distribution.
An assessment of the NICE Health Technology Assessment process and its strategic implications for pharmaceutical companies — covering appraisal types, submission evidence requirements, value-based pricing strategy, and how a positive NICE recommendation translates into NHS formulary access and Commercial Medicines Unit negotiations.
Publication Venue
Japan's foremost pharmaceutical industry daily — the primary source for pharmaceutical regulatory intelligence across Japan and Asia-Pacific.
| # | Title | Category | Year |
|---|---|---|---|
| 01 | UK Pharmaceutical Market Access Post-Brexit ↗ | Regulatory | 2024 |
| 02 | MHRA PLPI Licensing: A Practical Guide ↗ | MHRA | 2024 |
| 03 | Parallel Import Strategy in UK & EU Markets ↗ | Parallel Import | 2024 |
| 04 | NICE HTA: A Strategic Framework for NHS Market Entry ↗ | NHS Access | 2025 |
Contact
Reach out for pharmaceutical regulatory strategy discussions, media enquiries, article republishing, or investment and partnership opportunities.